RxSight (RXST) Common Equity (2020 - 2026)

RxSight (RXST) has 7 years of Common Equity data on file, last reported at $267.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 4.3% year-over-year to $267.3 million; the trailing twelve-month figure through Mar 2026 stood at $267.3 million (down 4.3% YoY), and the FY2025 full-year result was $275.7 million, down 1.98% from the prior year.
• Common Equity for Q1 2026 stood at $267.3 million, down from $275.7 million in the prior quarter.
• Across five years, Common Equity topped out at $281.2 million in Q4 2024 and bottomed at $89.9 million in Q4 2022.
• The 5-year median for Common Equity is $163.9 million (2024), against an average of $201.0 million.
• Peak annual rise in Common Equity reached 140.8% in 2022, while the deepest fall reached 36.41% in 2022.
• A 5-year view of Common Equity shows it stood at $89.9 million in 2022, then surged by 78.37% to $160.4 million in 2023, then surged by 75.38% to $281.2 million in 2024, then declined by 1.98% to $275.7 million in 2025, then declined by 3.04% to $267.3 million in 2026.
• The last three Common Equity figures came in at $267.3 million (Q1 2026), $275.7 million (Q4 2025), and $276.0 million (Q3 2025), per Business Quant data.

Peer Comparison